Jenburkt Pharmaceuticals has planned to launch Favipiravir-200 mg tablets, recommended for the treatment of mild to moderate COVID-19 patients.
Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.